Alector, Inc. reported financial results for the quarter ended June 30, 2026, on August 6, 2026. The company generated $3.3 million in collaboration revenue and incurred a net loss of $23.0 million, or $0.21 per share, compared to a net loss of $30.5 million in the prior year period. Research and development expenses decreased to $19.5 million from $27.6 million, while general and administrative expenses fell to $8.3 million from $14.4 million, primarily due to workforce reductions. As of June 30, 2026, Alector held $172.8 million in cash, cash equivalents, and investments, providing sufficient runway through at least 2027. The company also provided updates on its preclinical pipeline, selecting AL137 as the lead anti-amyloid beta antibody candidate for Alzheimer’s disease with an IND submission targeted for Q1 2027.

Alector is a biotechnology company focused on developing therapies to counteract neurodegenerative diseases using its proprietary Alector Brain Carrier platform.

Alector, Inc. announced the termination of its collaboration and license agreement with GSK, effective January 2, 2027, following clinical trial failures for latozinemab and nivisnebart. Additionally, the company repaid in full and terminated its loan and security agreement with Hercules Capital, Inc., paying an aggregate principal amount of $10,428,827.77 plus interest and charges. Alector, Inc. is a biotechnology company focused on developing investigational monoclonal antibodies for neurodegenerative diseases.